Crowdonomics
All companies
EYEDETEC MEDICAL logo

EYEDETEC MEDICAL

Operating

Eyedetec Medical, Inc

Healthcare · Founded 2010

Chronic dry eye therapy reamigined

Post-money valuation
$15.2M
As of Apr 2024 · from Eyedetec Medical Preferred Stock 1 · pre-money + amount raised, not a traded price
Total raised
$0
Across 1 round since 2024
Latest share price
$3.88
Eyedetec Medical Preferred Stock 1 offering price

Financials

FY2021–FY2022 · from SEC filings · hover any figure for its source
$362K
−$884K
2021
$412K
−$635K
2022
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2021
FY2022
Income statement
Revenue
$362,367
$411,720
Cost of goods sold
$180,311
$120,112
Gross margin
50%
71%
Net income
-$884,110
-$635,392
Taxes paid
$800
$0
Balance sheet
Cash
$407,228
$301,838
Accounts receivable
$17,385
$40,118
Total assets
$521,914
$451,362
Short-term debt
$703,247
$1,041,720
Long-term debt
$5,249,175
$5,475,542
Total liabilities
$5,952,422
$6,517,262
Other
Headcount
2

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Post-money = pre-money + amount raised · caps marked
$15.2M
post-money
Eyedetec Medical Preferred Stock 1

A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.

Fundraising history

Eyedetec Medical Preferred Stock 1WithdrawnReg CF · Preferred Equity · via StartEngine
Raised $0 / $1.2MInvestors 31Post-money $15.2M

Team

3 people
Barry Linder
President, CEO, Chairman of the Board, Principal Accounting Officer
Ronald Linder
COO, Director
LyeSum Linder
Director

Names and titles as disclosed on SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not obligated

never closed a Reg CF raise

31 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form C-UApr 23, 20240001665160-24-000454
    EDGAR
  • Form C/AFeb 29, 20240001665160-24-000148
    EDGAR
  • Form CFeb 22, 20240001665160-24-000105
    EDGAR
Source: ManualCIK 0001441817Share price $3.88

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.